Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 6Lymphoid 3Genitourinary 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Head & Neck 1CNS 1

Conditions

Urinary Bladder Neoplasms 2Neoplasms 1

Interventions

Docetaxel 390pembrolizumab 325Prednisone 284Gemcitabine 273enzalutamide 254Radiotherapy 251Nivolumab 247Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 197Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 98cabozantinib 97abiraterone 97Sorafenib 97atezolizumab 96Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Niacinamide × Genitourinary × Clear all
NCT07119996 2025-08-13

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1 Not yet recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neoplasms

NCT00033436 2013-09-20

Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Completed
330 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡